Loading...
•
Dec 31, 2023
CervoMed Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023 and provided corporate updates.
Key Takeaways
CervoMed reported its financial results for Q4 and full year 2023, highlighting advancements in their business, including a NASDAQ listing and the appointment of Joshua Boger, Ph.D., as Chair of the Board. The company is focused on the RewinD-LB Phase 2b trial for neflamapimod in DLB patients, with topline data expected in Q4 2024.
Announced a private placement of up to $149.4 million, expected to provide cash runway through the end of 2025.
On track to complete enrollment in the RewinD-LB Phase 2b clinical trial in Q2 2024, with topline data expected in Q4 2024.
Integrated summary of results from the AscenD-LB Phase 2a trial was published in a peer-reviewed journal and presented at a major scientific conference.
Appointed Joshua Boger, Ph.D., as Chair of the Board of Directors.
CervoMed
CervoMed
Forward Guidance
CervoMed anticipates completing enrollment in the RewinD-LB trial in Q2 2024 and expects topline data in Q4 2024. A private placement is expected to close on or about April 1, 2024, pending customary closing conditions.
Positive Outlook
- On track to complete enrollment in RewinD-LB trial in Q2 2024.
- Topline data from RewinD-LB trial expected in Q4 2024.
- Private placement expected to close on or about April 1, 2024.
- Upfront private placement funding of $50.0 million expected to be received on April 1, 2024.
- Cash position as of December 31, 2023, along with remaining funds, will enable funding through the end of 2025.
Challenges Ahead
- Forward-looking statements involve risks and uncertainties.
- Actual results could differ materially from those expressed or implied in forward-looking statements.
- Risks related to available cash resources and the availability of additional funds on acceptable terms.
- Risks related to the results of the Company’s clinical trials.
- Risks related to general economic, political, business, industry, and market conditions.